Immunoregulatory effects of myeloid-derived suppressor cell exosomes in mouse model of autoimmune Alopecia Areata

The treatment of autoimmune diseases still poses a major challenge, frequently relying on non-specific immunosuppressive drugs. Current efforts aim at reestablishing self tolerance using immune cells with suppressive activity like the regulatory T cells (Treg) or the myeloid-derived suppressor cells...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Zöller, Margot (VerfasserIn) , Zhao, Kun (VerfasserIn) , Kutlu, Natalia (VerfasserIn) , Bauer, Nathalie (VerfasserIn) , Provaznik, Jan (VerfasserIn) , Hackert, Thilo (VerfasserIn) , Schnölzer, Martina (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 06 June 2018
In: Frontiers in immunology
Year: 2018, Jahrgang: 9
ISSN:1664-3224
DOI:10.3389/fimmu.2018.01279
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2018.01279
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/articles/10.3389/fimmu.2018.01279/full
Volltext
Verfasserangaben:Margot Zöller, Kun Zhao, Natalia Kutlu, Nathalie Bauer, Jan Provaznik, Thilo Hackert and Martina Schnölzer
Beschreibung
Zusammenfassung:The treatment of autoimmune diseases still poses a major challenge, frequently relying on non-specific immunosuppressive drugs. Current efforts aim at reestablishing self tolerance using immune cells with suppressive activity like the regulatory T cells (Treg) or the myeloid-derived suppressor cells (MDSC). We have demonstrated therapeutic efficacy of MDSC in mouse Alopecia Areata (AA). In the same AA model, we now asked whether MDSC exosomes (MDSC-Exo) can replace MDSC. MDSC-Exo from bone marrow cells (BMC) cultures of healthy donors could substantially facilitate treatment. With knowledge on MDSC-Exo being lim¬ited, their suitability needs to be verified in advance. Protein marker profiles suggest comparability of BMC- to ex vivo collected inflam¬matory MDSC/MDSC-Exo in mice with a chronic contact dermatitis, which is a therapeutic option in AA. Proteome analyses substantiated a large overlap of function-relevant molecules in MDSC and MDSC-Exo. Furthermore, MDSC-Exo are taken up by T cells, macrophages, NK and most avidly by Treg and MDSC-Exo uptake exceeds binding of MDSC themselves. In AA mice, MDSC-Exo preferentially tar¬get skin-draining lymph nodes and cells in the vicinity of remnant hair follicles. MDSC-Exo uptake is accompanied by a strong increase in Treg, reduced T helper proliferation, mitigated cytotoxic activity and a slight increase in lymphocyte apoptosis. Repeated MDSC-Exo appli¬cation in florid AA prevented progression and sufficed for partial hair regrowth. Deep sequencing of lymphocyte mRNA from these mice revealed a significant increase in immu¬noregulatory mRNA, including FoxP3 and arginase 1. Downregulated mRNA was preferentially engaged in prohibiting T cell hyperreactivity. Taken together, proteome analysis provided important insights into potential MDSC-Exo activities, these exosomes preferentially homing into AA-affected organs. Most importantly, changes in leukocyte mRNA seen after treatment of AA mice with MDSC-Exo sustainably supports the strong impact on the adaptive and the non-adaptive immune system, with Treg expansion being a dominant feature. Thus, MDSC-Exo could potentially serve as therapeutic agents in treating AA and other autoim¬mune diseases.
Beschreibung:Gesehen am 13.11.2019
Beschreibung:Online Resource
ISSN:1664-3224
DOI:10.3389/fimmu.2018.01279